These Analysts Increase Their Forecasts On Gilead Sciences After Upbeat Q3 Results
Gilead beats Q3 estimates, raises 2026 sales guidance but cuts EPS outlook; shares rise 4.1% as analysts lift price targets.
Share
Why It Matters
Gilead did better than expected this quarter and made more money. Experts now think the company will earn more, so they raised their price targets.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.